# Glaxo Wellcome clinical trials: 72 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 72 trials with Glaxo Wellcome as lead sponsor, 0 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Glaxo Wellcome: 72 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/glaxo-wellcome

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 72
- Recruiting or not yet: 0
- Read on: November 19, 2026

## Trials

The 25 newest of 72, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| August 31, 2001 | NCT00009061 | Comparison of GW433908/Ritonavir to Nelfinavir When Used With Abacavir and Lamivudine in Patients That Have Not Taken Antiretroviral Drugs | Glaxo Wellcome | Phase 3 | Unknown | HIV Infections | 624 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00009061) |
| August 31, 2001 | NCT00008554 | Comparison of GW433908 and Nelfinavir in HIV Patients Who Have Not Had Antiretroviral Therapy | Glaxo Wellcome | Phase 3 | Unknown | HIV Infections | 210 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00008554) |
| August 31, 2001 | NCT00005764 | A Study of Increased Lactic Acid and Abnormal Fat Distribution in HIV-Positive Patients | Glaxo Wellcome | Phase 4 | Completed | HIV Infections, Lipodystrophy | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00005764) |
| August 31, 2001 | NCT00005663 | A Study of Valacyclovir as Treatment for Genital Herpes Simplex Virus in HIV-Infected Patients | Glaxo Wellcome | Phase 3 | Unknown | Herpes Simplex, HIV Infections, Herpes Genitalis | Not listed | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00005663) |
| August 31, 2001 | NCT00005106 | A Comparison of Three Anti-HIV Drug Combinations in HIV-Infected Patients | Glaxo Wellcome | Phase 4 | Completed | HIV Infections | 230 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00005106) |
| August 31, 2001 | NCT00005018 | Safety and Effectiveness of a Combination Anti-HIV Drug Treatment | Glaxo Wellcome | Phase 4 | Completed | HIV Infections | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00005018) |
| August 31, 2001 | NCT00005017 | Effectiveness and Safety of Epivir/Ziagen/Zerit (3TC/ABC/d4T) Versus Epivir/Ziagen/Sustiva (3TC/ABC/EFV) Versus... | Glaxo Wellcome | Phase 4 | Unknown | HIV Infections | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00005017) |
| August 31, 2001 | NCT00004981 | Safety and Effectiveness of Three Anti-HIV Drugs Combined in One Pill (Trizivir) | Glaxo Wellcome | Phase 3 | Unknown | HIV Infections | 230 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00004981) |
| August 31, 2001 | NCT00004852 | Safety and Effectiveness of Lamivudine When Given Once a Day Versus Twice a Day in Combination With Other Anti-HIV Drugs in HIV-Infected... | Glaxo Wellcome | Phase 2 | Completed | HIV Infections | Not listed | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00004852) |
| August 31, 2001 | NCT00004585 | A Study of the Safety and Effectiveness of Combination Anti-HIV Therapy in HIV-Infected Adults | Glaxo Wellcome | Phase 4 | Completed | HIV Infections | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00004585) |
| August 31, 2001 | NCT00002442 | A Study to Compare the Safety and Effectiveness of Two Dosing Schedules of Lamivudine in Combination With Two Other Anti-HIV Drugs | Glaxo Wellcome | Phase 2 | Completed | HIV Infections | Not listed | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00002442) |
| August 31, 2001 | NCT00002440 | A Study of 1592U89 in Combination With Protease Inhibitors in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs | Glaxo Wellcome | Phase 2 | Completed | HIV Infections | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00002440) |
| August 31, 2001 | NCT00002436 | The Safety and Effectiveness of Three Anti-HIV Drug Combinations in HIV-Infected Patients Who Have Taken AZT | Glaxo Wellcome | Phase 3 | Completed | HIV Infections | 325 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00002436) |
| August 31, 2001 | NCT00002423 | A Study to Compare Two Anti-HIV Drug Combinations That Include Amprenavir in HIV-Infected Patients Who Have Failed Anti-HIV Drug... | Glaxo Wellcome | Phase 2 | Completed | HIV Infections | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00002423) |
| August 31, 2001 | NCT00002417 | A Study of Amprenavir in Patients With Protease Inhibitor-Related Complications | Glaxo Wellcome | Not applicable | Completed | HIV Infections | Not listed | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00002417) |
| August 31, 2001 | NCT00002409 | The Effect of Teaching HIV-Infected Patients About HIV and Treatment | Glaxo Wellcome | Phase 3 | Completed | HIV Infections | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00002409) |
| August 31, 2001 | NCT00002405 | A Study of Amprenavir in HIV-Infected Patients | Glaxo Wellcome | Not applicable | Completed | HIV Infections | Not listed | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00002405) |
| August 31, 2001 | NCT00002404 | The Effect of Valacyclovir on the Detection of HIV From Genital Herpes Lesions in HIV-Infected Patients | Glaxo Wellcome | Not applicable | Completed | Herpes Simplex, HIV Infections | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00002404) |
| August 31, 2001 | NCT00002391 | The Safety and Effectiveness of Zidovudine Plus Lamivudine, Used With and Without 1592U89, in HIV-1 Infected Children Who Have Taken... | Glaxo Wellcome | Phase 3 | Completed | HIV Infections | Not listed | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00002391) |
| August 31, 2001 | NCT00002390 | A Study of the Safety and Effectiveness of Different Doses of 1592U89 in HIV-Infected Patients | Glaxo Wellcome | Phase 2 | Completed | HIV Infections | Not listed | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00002390) |
| August 31, 2001 | NCT00002389 | The Safety and Effectiveness of Lamivudine Plus Zidovudine, Used With and Without 1592U89, in HIV-1 Infected Patients Who Have Never Taken... | Glaxo Wellcome | Phase 3 | Completed | HIV Infections | 210 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00002389) |
| August 31, 2001 | NCT00002388 | A Study of 1592U89 in HIV-Infected Patients | Glaxo Wellcome | Phase 1 | Completed | HIV Infections | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00002388) |
| August 31, 2001 | NCT00002373 | The Safety and Effectiveness of Different Dose Levels of 1263W94 in the Treatment of Cytomegalovirus (CMV) of the Eyes in HIV-Infected... | Glaxo Wellcome | Phase 1 | Completed | Cytomegalovirus Infections, HIV Infections | 56 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00002373) |
| August 31, 2001 | NCT00002372 | A Study of 141W94 in Combination With Other Anti-HIV Drugs | Glaxo Wellcome | Phase 1 | Completed | HIV Infections | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00002372) |
| August 31, 2001 | NCT00002364 | A Study of 1592U89 Combined With Other Anti-HIV Drugs in Patients Who Have Taken Anti-HIV Drugs | Glaxo Wellcome | Phase 2 | Completed | HIV Infections | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00002364) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 8 |
| Phase 2 | 11 |
| Phase 3 | 17 |
| Phase 4 | 5 |
| Not applicable | 31 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 67 |
| Unknown | 5 |

## Conditions

| Condition group | Trials |
| --- | --- |
| HIV Infections | 72 |
| Acquired Immunodeficiency Syndrome | 26 |
| AIDS-Related Complex | 21 |
| Pneumonia, Pneumocystis | 4 |
| Herpes Simplex | 4 |
| Herpes Genitalis | 4 |
| Patient Compliance | 3 |
| Lipodystrophy | 3 |
| AIDS-Related Opportunistic Infections | 3 |
| Anus Diseases | 3 |
| AIDS Dementia Complex | 2 |
| Recurrence | 2 |
| Psoriasis | 1 |
| Hyperlipidemias | 1 |
| Toxoplasmosis, Cerebral | 1 |
| Toxoplasmosis | 1 |
| Encephalitis | 1 |
| Lymphatic Diseases | 1 |
| Chickenpox | 1 |
| Herpes Zoster | 1 |
| Cytomegalovirus Infections | 1 |
| Leukoplakia, Hairy | 1 |
| Leukoplakia, Oral | 1 |
| Epstein-Barr Virus Infections | 1 |
| Neuromuscular Diseases | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Sand and gravel suppliers in the United States](https://specstream.ai/data/businesses/sand-and-gravel-suppliers/united-states)
- [Kitchen supply stores in the United States](https://specstream.ai/data/businesses/kitchen-supply-stores/united-states)
- [Dental laboratories in the United States](https://specstream.ai/data/businesses/dental-laboratories/united-states)
- [Adult education centers in the United States](https://specstream.ai/data/businesses/adult-education-centers/united-states)
- [Printing companies in the United States](https://specstream.ai/data/businesses/printing-companies/united-states)
- [Hostels in the United States](https://specstream.ai/data/businesses/hostels/united-states)
